LFB

LFB is a French biopharmaceutical group that develops, produces, and markets plasma-derived medicinal products and recombinant proteins. Founded in 1994, LFB has established itself as a leading player in Europe, operating in over 30 countries and employing around 3,000 people as of 2024. The company specializes in three main therapeutic areas: immunology, haemostasis, and intensive care. LFB's product portfolio includes approximately fifteen biomedicinal products aimed at addressing unmet medical needs in these fields. It is recognized as the leading manufacturer of plasma-derived medicinal products in France and ranks fifth worldwide. The company operates five bioproduction sites globally and is committed to research and development to enhance its therapeutic offerings. LFB is wholly owned by the French State and includes two main subsidiaries: LFB Biomedicaments and LFB Biotechnologies. Its mission focuses on providing innovative treatment options to improve patient outcomes for those with serious and rare diseases.